We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Alimera Sciences is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Alimera Sciences is a member of the Medical sector. This group includes 1186 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Alimera Sciences is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALIM's full-year earnings has moved 11.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ALIM has moved about 30.6% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -14.4% on a year-to-date basis. As we can see, Alimera Sciences is performing better than its sector in the calendar year.
Another stock in the Medical sector, Centene (CNC - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 16.9%.
For Centene, the consensus EPS estimate for the current year has increased 3.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Alimera Sciences belongs to the Medical - Biomedical and Genetics industry, a group that includes 557 individual stocks and currently sits at #71 in the Zacks Industry Rank. This group has lost an average of 17% so far this year, so ALIM is performing better in this area.
In contrast, Centene falls under the Medical - HMOs industry. Currently, this industry has 8 stocks and is ranked #65. Since the beginning of the year, the industry has moved +9.4%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Alimera Sciences and Centene as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Alimera Sciences is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Alimera Sciences is a member of the Medical sector. This group includes 1186 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Alimera Sciences is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALIM's full-year earnings has moved 11.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ALIM has moved about 30.6% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -14.4% on a year-to-date basis. As we can see, Alimera Sciences is performing better than its sector in the calendar year.
Another stock in the Medical sector, Centene (CNC - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 16.9%.
For Centene, the consensus EPS estimate for the current year has increased 3.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Alimera Sciences belongs to the Medical - Biomedical and Genetics industry, a group that includes 557 individual stocks and currently sits at #71 in the Zacks Industry Rank. This group has lost an average of 17% so far this year, so ALIM is performing better in this area.
In contrast, Centene falls under the Medical - HMOs industry. Currently, this industry has 8 stocks and is ranked #65. Since the beginning of the year, the industry has moved +9.4%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Alimera Sciences and Centene as they could maintain their solid performance.